GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Urologix Inc (OTCPK:ULGX) » Definitions » Cyclically Adjusted PB Ratio

Urologix (Urologix) Cyclically Adjusted PB Ratio : (As of Apr. 29, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Urologix Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Urologix Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Urologix's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urologix Cyclically Adjusted PB Ratio Chart

Urologix Annual Data
Trend Jun05 Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Urologix Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Urologix's Cyclically Adjusted PB Ratio

For the Medical Devices subindustry, Urologix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Urologix's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Urologix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Urologix's Cyclically Adjusted PB Ratio falls into.



Urologix Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Urologix's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2015 is calculated as:

For example, Urologix's adjusted Book Value per Share data for the three months ended in Mar. 2015 was:

Adj_Book=Book Value per Share/CPI of Mar. 2015 (Change)*Current CPI (Mar. 2015)
=-0.379/99.6211*99.6211
=-0.379

Current CPI (Mar. 2015) = 99.6211.

Urologix Quarterly Data

Book Value per Share CPI Adj_Book
200506 2.317 82.062 2.813
200509 2.352 83.876 2.794
200512 2.398 83.032 2.877
200603 2.446 84.298 2.891
200606 2.790 85.606 3.247
200609 2.778 85.606 3.233
200612 2.805 85.142 3.282
200703 2.769 86.640 3.184
200706 1.945 87.906 2.204
200709 1.933 87.964 2.189
200712 1.242 88.616 1.396
200803 1.106 90.090 1.223
200806 0.966 92.320 1.042
200809 0.877 92.307 0.946
200812 0.814 88.697 0.914
200903 0.738 89.744 0.819
200906 0.689 91.003 0.754
200909 0.650 91.120 0.711
200912 0.641 91.111 0.701
201003 0.605 91.821 0.656
201006 0.568 91.962 0.615
201009 0.525 92.162 0.567
201012 0.483 92.474 0.520
201103 0.421 94.283 0.445
201106 0.334 95.235 0.349
201109 0.249 95.727 0.259
201112 0.180 95.213 0.188
201203 0.120 96.783 0.124
201206 0.043 96.819 0.044
201209 0.169 97.633 0.172
201212 0.123 96.871 0.126
201303 0.077 98.209 0.078
201306 0.020 98.518 0.020
201309 -0.041 98.790 -0.041
201312 -0.090 98.326 -0.091
201403 -0.167 99.695 -0.167
201406 -0.333 100.560 -0.330
201409 -0.351 100.428 -0.348
201412 -0.363 99.070 -0.365
201503 -0.379 99.621 -0.379

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Urologix  (OTCPK:ULGX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Urologix Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Urologix's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Urologix (Urologix) Business Description

Traded in Other Exchanges
N/A
Address
14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.
Executives
Emery Sidney W Jr director C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Patrick D Spangler director 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Gregory Fluet director, officer: CEO 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
William M Moore director
Guy C Jackson director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Claude Tihon officer: Chief Technology Officer
Bobby Ivan Griffin director 1326 SPRING VALLEY RD GOLDEN VALLEY PA 55422
David A Montecalvo officer: VP, Product Dev. & Operations 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Susan Bartlett Foote director 649 SUMMIT AVENUE, ST PAUL MN 55105

Urologix (Urologix) Headlines

From GuruFocus

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 16,900 Shares

By GuruFocus Research GuruFocus Editor 12-09-2009

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 3,100 Shares

By GuruFocus Research GuruFocus Editor 12-07-2009

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 5,200 Shares

By GuruFocus Research GuruFocus Editor 02-01-2011

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-17-2010

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-21-2009